rAAVen Therapeutics

What rAAVen Therapeutics does

rAAVen Therapeutics is a Swedish privately-held biotech company founded in 2022 and headquartered at Medicon Village in Lund, Sweden. The company engineers rationally designed adeno-associated virus (AAV) capsids for gene therapy applications, serving biotech and pharmaceutical developers that require targeted in vivo delivery to specific tissues and cell types. rAAVen addresses the central bottleneck in gene therapy — efficient and selective delivery — by exploiting conserved receptor-ligand interactions across mammalian species to design short, evolution-inspired peptide motifs that bias capsid libraries toward variants with desired tropism and trafficking properties.

The company's core technology is the rAAptr (rational AAV Peptide Research) platform, which integrates rational peptide design, DNA barcoded AAV libraries, high-throughput next-generation sequencing, and in vivo screening in rodent and non-human primate (NHP) models. Each capsid variant is linked to a unique DNA barcode, enabling quantitative, high-resolution mapping of capsid performance across tissues and cell types in a single experiment. The platform has produced multiple rationally designed libraries targeting distinct indications, including AAV-Swift (brain/intraparenchymal delivery, demonstrating performance at up to 10,000x lower doses than wild-type AAV2), AAV-Goose (renal glomerular cells), AAV-Luzon (cardiac), AAV-Roadrunner (skeletal muscle), and AAV-Cassowary (pancreatic islets). An ongoing research project called Colibri combines diffusion-based generative models and message-passing neural networks for in silico capsid design.

rAAVen operates a pure B2B partnership/collaboration model, engaging biotech and pharmaceutical companies directly — including Myrtelle Inc. (oligodendrocyte targeting, ongoing since 2022) and Prevail Therapeutics (CNS disorders, since 2024) — through bespoke contracts ranging from focused capsid discovery to multi-program portfolios. Typical engagement timelines run 5-16 months depending on scope (validation of top capsids: 5 months; existing library screening: 12 months; de novo library design with NHP screening: 16 months). Pricing is not publicly disclosed. The company is led by Founder & CEO Marcus Davidsson, PhD, and CSO Patrick Aldrin-Kirk, PhD, with a leadership team of fewer than 10 employees and generates revenue through milestone-based professional services agreements.

Name

rAAVen Therapeutics

Legal name

rAAVen Therapeutics

Website

https://raaven.se

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

rAAVen Therapeutics is a Swedish biotech (founded 2022, Lund) that rationally engineers AAV capsids for gene therapy delivery, serving biotech and pharma developers through B2B partnership agreements on its rAAptr platform combining rational peptide design, DNA barcoding, and NHP screening.

Ownership category

akta.pro rank

Product category

AAV capsid engineering / Gene therapy delivery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)

akta.pro secondary industries

Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral) (HLAAAKAD), Gene Therapy for Rare/Monogenic Diseases (HLAAACAE)

Keywords

• AAV capsid engineering
• Gene therapy delivery
• Viral vector design
• Rational capsid discovery
• DNA barcoded libraries

Headquarters

HQ city

Lund

HQ country

Sweden

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Partnership/Collaboration Services: B2B partnerships with biotech and pharma companies for AAV capsid engineering services. They offer de novo library design (10-100 million AAVs), screening of existing libraries, and validation of top AAV capsids. Flexible partnership models from focused capsid discovery projects to broader multi-program capsid portfolios.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

rAAVen Therapeutics engineers novel adeno-associated virus (AAV) capsids for targeted gene therapy delivery. Using its rAAptr platform — which combines rational peptide design, DNA barcoded AAV libraries, and high-throughput next-generation sequencing — the company designs, screens, and validates AAV capsids with precise tropism for specific tissues and cell types. Services are delivered through bespoke B2B collaborations with biotech and pharmaceutical companies developing gene therapies.

Product overview

rAAVen Therapeutics offers a unified platform-plus-services model centered on the rAAptr (rational AAV Peptide Research) platform. The platform integrates rational peptide design, DNA barcoded AAV libraries, and high-throughput next-generation sequencing to engineer and discover AAV capsids with precise tropism for specific tissues and cell types. The company provides multiple rationally designed AAV library products including AAV-Goose (renal glomerular cells), AAV-Luzon (cardiac), AAV-Roadrunner (skeletal muscle), AAV-Cassowary (pancreatic islets), and AAV-Swift (brain/intraparenchymal), plus the research-stage Colibri project using generative AI. Completed partnership programs include Kingfisher (oligodendrocyte targeting with Myrtelle) and Bluejay (CNS targeting with Prevail). Services include custom de novo library design, existing library screening, and capsid validation across diverse organs and delivery routes.

Differentiator

Problem solved

Functional benefit

Products and services

• rAAptr Platform Integrated discovery and validation platform combining rational peptide design, DNA barcoded AAV libraries, and high-throughput next-generation sequencing for engineering AAV capsids with precise tropism across organs and cell types; sold/licensed via B2B collaborations to biotech and pharma partners developing gene therapies.
• Partnering Services Flexible B2B partnership services including de novo library design (10–100 million AAVs, 16-month NHP screening), screening of existing libraries (12-month NHP screening), and top-capsid validation (5-month validation), for biotech and pharma partners.
• AAV-Goose Rationally designed AAV library for efficient targeting of renal glomerular cells following IV delivery, showing robust and selective glomerular transduction in rodents. Available for partnering.
• AAV-Luzon Engineered AAV library for efficient targeting of heart cells after IV injection, achieving strong and widespread cardiac transduction in non-human primates. Available for partnering.
• AAV-Roadrunner Designed AAV library for efficient skeletal muscle targeting via IV delivery, driving high-level expression across major muscle groups in non-human primates. Available for partnering.
• AAV-Cassowary Designed AAV library for efficient pancreatic Langerhans islet targeting via IV delivery, driving high-level expression across alpha and beta cells in non-human primates. Available for partnering.
• AAV-Swift Rationally engineered AAV vector family designed to maximize spread and transduction in the brain following intraparenchymal injection, demonstrating markedly improved distribution at up to 10,000x lower vector doses compared to wild-type AAV2.
• Kingfisher AAV library engineered to target oligodendrocytes with high precision and strong enrichment in white-matter cell populations. Developed in collaboration with Myrtelle Inc.; five lead capsids identified that markedly outperform established benchmarks.
• Bluejay Collaboration with Prevail Therapeutics to develop novel AAV capsids for disorders of the nervous system. rAAVen leads capsid engineering, discovery, screening, and validation; Prevail handles preclinical development, manufacturing, and clinical advancement.
• Colibri Project utilizing diffusion-based generative models and message-passing neural networks for end-to-end in silico design of receptor-targeting AAV capsid variant libraries, combined with experimental screening in vitro and in vivo.

Quantifiable outcome

• Top capsids outperform established oligodendrocyte-targeting benchmarks in intraventricular delivery studies
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Partnerships

Five partnerships are on record, tiered minor and core.

• CYNBIOSEminorStrategic or Co-development Partner · 21 January 2025AAV screening assay collaboration in non-human primates. rAAVen worked with CYNBIOSE team including Joachim Confais and Alexia Aufrere on AAV screening in Lyon.
• CRCL (Centre de Recherche en Cancérologie de Lyon)minorStrategic or Co-development Partner · 21 January 2025AAV screening collaboration in non-human primates. Worked with CRCL team comprising Cyril Dégletagne, Thibault Andrieu, Priscillia Battiston-Montagne, Mélina Gautier and Samantha Ballesta.
• Prevail TherapeuticscoreStrategic or Co-development Partner · 2 April 2024Partnership to develop novel AAV capsids for disorders of the nervous system. rAAVen leads capsid engineering, discovery, screening, and validation, while Prevail drives preclinical development, manufacturing, and clinical advancement to bring new CNS gene therapies to patients.
• PCI BiotechminorStrategic or Co-development Partner · 4 May 2023Joint Photochemical Lysis project. rAAVen develops and produces AAV as well as performs research within the collaboration.
• Myrtelle Inc.coreStrategic or Co-development Partner · 22 June 2022Partnership to develop novel AAV capsids targeting oligodendrocytes. rAAVen and Myrtelle collaborated on intraventricular screening that identified five lead capsids outperforming established oligodendrocyte-targeting benchmarks. Several novel AAV capsid variants were successfully validated through intrastriatal and intraventricular injections. The partnership was later expanded for continuous validation of capsids from the oligodendrocyte screening assay.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Dyno Therapeutics: Dyno Therapeutics engineers novel AAV capsids using AI-driven design and high-throughput in vivo screening, directly competing with rAAVen's capsid engineering platform. Both serve gene therapy developers seeking targeted delivery solutions and pursue similar Big Pharma licensing models.
• 4D Molecular Therapeutics: 4DMT invents and evolves customized AAV capsids for therapeutic gene delivery across multiple indications, with a Therapeutic Vector Evolution platform that parallels rAAVen's rational design + screening approach. Both license or develop capsid-based gene therapies targeting specific tissues.
• StrideBio: StrideBio engineers novel AAV capsids through structure-guided design and directed evolution to improve tropism and reduce immunogenicity for gene therapy applications. Direct competitor in the engineered-AAV-capsid space serving similar biotech and pharma partners.
• Affinia Therapeutics: Affinia Therapeutics designs AAV capsids with enhanced tissue selectivity and payload capacity for gene therapy. Directly comparable to rAAVen in offering engineered capsid platforms to gene therapy developers across multiple therapeutic areas.
• Voyager Therapeutics: Voyager Therapeutics develops AAV capsid technology (TRACER platform) for CNS gene therapy, using directed evolution to generate tissue-targeted capsids. Comparable to rAAVen's CNS programs (AAV-Swift, Bluejay, Kingfisher) and broader capsid engineering approach.
• Apertura Gene Therapy: Apertura engineers AAV capsids using AI-guided design and high-throughput screening to address limitations of natural serotypes. Directly comparable platform-approach competitor targeting gene therapy developers with novel capsid solutions.

Broad incumbents

• Spark Therapeutics: Spark Therapeutics (a Roche subsidiary) is an established gene therapy company that uses AAV-based platforms for approved and clinical-stage therapies. While broader than rAAVen and focused on drug development rather than capsid licensing, Spark is a potential partner/customer and shapes market expectations for AAV gene therapy economics.

Regional players

• VIVEbiotech: VIVEbiotech is a Spanish CDMO specializing in AAV and lentiviral vector manufacturing for gene therapy developers. Comparable as a European-based AAV services provider, though focused on manufacturing scale rather than capsid engineering design.
• Yposkesi: Yposkesi is a French CDMO producing viral vectors (AAV, lentiviral) for gene therapy. Comparable as a European AAV service provider, offering manufacturing rather than capsid engineering capabilities relevant to rAAVen's partner ecosystem.

Emerging players

• PackGene Biotech: PackGene Biotech offers AAV vector design, engineering, and manufacturing services for gene therapy research. Comparable emerging platform offering capsid and vector services to gene therapy developers, with overlapping customer profile.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/raaven-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about rAAVen Therapeutics